Analysts/Institutional Investor Meet/Con. Call Updates

16th October, 2026 BSE Limited National Stock Exchange of India Limited P.J. Towers, Dalal Street, Fort, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (East), Mumbai – 400 051 BSE scrip code: 543635 NSE symbol: PPLPHARMA Sub: Intimation of Conference Call with Investors/Analysts under the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 (‘SEBI Listing Regulations’) Dear Sir / Madam, Pursuant to Regulation 30(6) of the SEBI Listing Regulations, please find enclosed herewith the details of the Conference call with investors/ analysts. Kindly take this on record. Thanking you, Yours truly, For Piramal Pharma Limited Maneesh Sharma Company Secretary & Compliance Officer Encl: a/a Piramal Pharma Limited CIN: L24297MH2020PLC338592 Registered Office: Ananta Building, Piramal Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070, Maharashtra, India Tel No. +91 22 3802 3000 / 4000; Email Id: shareholders.ppl@piramal.com www.piramalpharma.com Q2 and H1 FY2027 Earnings Conference Call Piramal Pharma Limited will be hosting a conference call for investors / analysts on 28th October 2026 from 10:00 AM to 10:45 AM (IST) to discuss its Q2 and H1 FY2027 Results The dial-in details for the call are as under: Event Location & Time Telephone Number +91 22 6280 1461 / +91 22 7115 8320 (Primary India – 10:00 AM IST Number) 1 800 120 1221 (Toll free number) USA – 12:30 AM Toll free number (Eastern Time – New York) 1 866 746 2133 Conference call on UK – 04:30 AM Toll free number 28th October 2026 (London Time) 0 808 101 1573 Singapore – 12:30 PM Toll free number (Singapore Time) 800 101 2045 Hong Kong – 12:30 PM Toll free number (Hong Kong Time) 800 964 448 Express Join with Please use this link for prior registration to reduce wait time at the time of joining Diamond Pass™ the call – Click Here About Piramal Pharma Ltd: Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the Piramal Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. For more information, visit: Piramal Pharma | LinkedIn For Queries: Gagan Borana Investor Relations & Enterprise Risk Management gagan.borana@piramal.com Page 1 of 1